IL296080B2 - Method for treating cancer - Google Patents
Method for treating cancerInfo
- Publication number
- IL296080B2 IL296080B2 IL296080A IL29608022A IL296080B2 IL 296080 B2 IL296080 B2 IL 296080B2 IL 296080 A IL296080 A IL 296080A IL 29608022 A IL29608022 A IL 29608022A IL 296080 B2 IL296080 B2 IL 296080B2
- Authority
- IL
- Israel
- Prior art keywords
- amount
- compound
- formulation
- pharmaceutical formulation
- solid pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462080985P | 2014-11-17 | 2014-11-17 | |
| US201562166572P | 2015-05-26 | 2015-05-26 | |
| US201562251903P | 2015-11-06 | 2015-11-06 | |
| PCT/US2015/061194 WO2016081523A1 (en) | 2014-11-17 | 2015-11-17 | Method for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL296080A IL296080A (en) | 2022-11-01 |
| IL296080B1 IL296080B1 (en) | 2023-08-01 |
| IL296080B2 true IL296080B2 (en) | 2023-12-01 |
Family
ID=56014476
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL296080A IL296080B2 (en) | 2014-11-17 | 2015-11-17 | Method for treating cancer |
| IL304252A IL304252B2 (en) | 2014-11-17 | 2015-11-17 | Method for treating cancer |
| IL252182A IL252182B2 (en) | 2014-11-17 | 2017-05-09 | Cancer treatment methods |
| IL323396A IL323396A (en) | 2014-11-17 | 2025-09-16 | Cancer treatment methods |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304252A IL304252B2 (en) | 2014-11-17 | 2015-11-17 | Method for treating cancer |
| IL252182A IL252182B2 (en) | 2014-11-17 | 2017-05-09 | Cancer treatment methods |
| IL323396A IL323396A (en) | 2014-11-17 | 2025-09-16 | Cancer treatment methods |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10786511B2 (enExample) |
| EP (2) | EP3220916B1 (enExample) |
| JP (3) | JP6829684B2 (enExample) |
| KR (3) | KR102964530B1 (enExample) |
| CN (2) | CN107249591B (enExample) |
| AU (4) | AU2015350108B2 (enExample) |
| BR (1) | BR112017010166A2 (enExample) |
| DK (1) | DK3220916T3 (enExample) |
| EA (1) | EA201791095A1 (enExample) |
| ES (1) | ES2947819T3 (enExample) |
| FI (1) | FI3220916T3 (enExample) |
| HU (1) | HUE062159T2 (enExample) |
| IL (4) | IL296080B2 (enExample) |
| LT (1) | LT3220916T (enExample) |
| MX (2) | MX383484B (enExample) |
| PL (1) | PL3220916T3 (enExample) |
| PT (1) | PT3220916T (enExample) |
| SG (1) | SG11201703806XA (enExample) |
| SI (1) | SI3220916T1 (enExample) |
| WO (1) | WO2016081523A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| KR20190105669A (ko) | 2012-10-15 | 2019-09-17 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| MX373187B (es) | 2013-12-06 | 2020-04-13 | Epizyme Inc | Terapia de combinación para tratar cáncer. |
| EA038337B1 (ru) | 2014-06-17 | 2021-08-11 | Эпизим, Инк. | Ингибиторы ezh2 для лечения лимфомы |
| KR102964530B1 (ko) | 2014-11-17 | 2026-05-13 | 에피자임, 인코포레이티드 | 암을 치료하기 위한 방법 |
| MX391720B (es) | 2015-04-20 | 2025-03-21 | Epizyme Inc | Terapia combinada para tratar cáncer. |
| EA201890009A1 (ru) | 2015-06-10 | 2018-07-31 | Эпизайм, Инк. | Ингибиторы ezh2 для лечения лимфомы |
| WO2017035234A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| US11951108B2 (en) | 2016-01-29 | 2024-04-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| US11786533B2 (en) | 2016-06-01 | 2023-10-17 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| BR112019014924A2 (pt) | 2017-01-19 | 2020-03-31 | St. Marianna University School Of Medicine | Composição farmacêutica usada para o tratamento de mielopatia associada ao htlv-1 |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2018275123A1 (en) | 2017-06-02 | 2020-01-30 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| JP7399079B2 (ja) | 2017-09-05 | 2023-12-15 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| KR20220130698A (ko) * | 2019-12-20 | 2022-09-27 | 에피자임, 인코포레이티드 | Ezh2 억제제의 결정질 하이드로브로마이드 염, 이의 제조 및 암의 치료에 유용한 약학적 조성물 |
| JP7628876B2 (ja) | 2021-04-23 | 2025-02-12 | 日立Astemo株式会社 | 情報処理装置、情報処理方法、プログラムおよび記憶媒体 |
| WO2023159124A2 (en) * | 2022-02-17 | 2023-08-24 | Memorial Sloan-Kettering Cancer Center | Methods for overcoming tazemetostat-resistance in cancer patients |
| CA3249707A1 (en) | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH AN EZH1 AND/OR EZH2 INHIBITOR |
| WO2026117542A1 (en) | 2024-11-26 | 2026-06-04 | Arvinas Operations, Inc. | Combination therapy for the targeted degradation of bcl6 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9119052D0 (en) | 1991-09-06 | 1991-10-23 | Boots Co Plc | Pharmaceutical compositions |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US20070026064A1 (en) * | 2005-07-29 | 2007-02-01 | Yoder Steven L | Pharmaceutical dosage forms having watermark-type identification and authentication inditia |
| WO2008121476A1 (en) * | 2007-03-28 | 2008-10-09 | Tapestry Pharmaceuticals, Inc. | Biologically active taxane analogs and methods of treatment by oral administration |
| US20100278921A1 (en) * | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| EP2663283B1 (en) * | 2011-01-14 | 2017-05-10 | Bristol-Myers Squibb Company | High drug load tablet formulation of brivanib alaninate |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| CA3177515A1 (en) | 2012-03-12 | 2013-09-19 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
| ES2617379T3 (es) | 2012-04-13 | 2017-06-16 | Epizyme, Inc. | Forma de sal de un inhibidor de histona metiltransferasa EZH2 humana |
| EP2836216B1 (en) * | 2012-04-13 | 2022-06-08 | Epizyme, Inc. | Combination therapy for treating cancer |
| KR20190105669A (ko) * | 2012-10-15 | 2019-09-17 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| BR112015008480A2 (pt) | 2012-10-15 | 2017-07-04 | Epizyme Inc | compostos de benzeno substituído |
| EP2934531A4 (en) * | 2012-12-19 | 2016-06-15 | Glaxosmithkline Llc | COMBINATION |
| CA2894216A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone compounds |
| CA2894222A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| US20160031907A1 (en) | 2013-03-15 | 2016-02-04 | Epizyme, Inc. | Substituted Benzene Compounds |
| EP2970306A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS |
| EP3022184B1 (en) | 2013-07-19 | 2017-09-27 | Epizyme, Inc. | Substituted benzene compounds |
| PE20161273A1 (es) * | 2013-10-16 | 2016-12-18 | Epizyme Inc | Forma salina de hidrocloruro para la inhibicion de ezh2 |
| WO2015058125A1 (en) * | 2013-10-18 | 2015-04-23 | Epizyme, Inc. | Method of treating cancer |
| MX373187B (es) | 2013-12-06 | 2020-04-13 | Epizyme Inc | Terapia de combinación para tratar cáncer. |
| EA038337B1 (ru) * | 2014-06-17 | 2021-08-11 | Эпизим, Инк. | Ингибиторы ezh2 для лечения лимфомы |
| EP3160940A4 (en) | 2014-06-25 | 2018-05-02 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
| CN106794177A (zh) | 2014-10-16 | 2017-05-31 | Epizyme股份有限公司 | 治疗癌症的方法 |
| KR102964530B1 (ko) | 2014-11-17 | 2026-05-13 | 에피자임, 인코포레이티드 | 암을 치료하기 위한 방법 |
| EA201890009A1 (ru) * | 2015-06-10 | 2018-07-31 | Эпизайм, Инк. | Ингибиторы ezh2 для лечения лимфомы |
| US11147819B2 (en) * | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
-
2015
- 2015-11-17 KR KR1020247007271A patent/KR102964530B1/ko active Active
- 2015-11-17 HU HUE15860676A patent/HUE062159T2/hu unknown
- 2015-11-17 JP JP2017526088A patent/JP6829684B2/ja active Active
- 2015-11-17 CN CN201580063476.2A patent/CN107249591B/zh active Active
- 2015-11-17 PL PL15860676.4T patent/PL3220916T3/pl unknown
- 2015-11-17 PT PT158606764T patent/PT3220916T/pt unknown
- 2015-11-17 CN CN202310518396.8A patent/CN116650500B/zh active Active
- 2015-11-17 AU AU2015350108A patent/AU2015350108B2/en active Active
- 2015-11-17 IL IL296080A patent/IL296080B2/en unknown
- 2015-11-17 KR KR1020217040314A patent/KR102644844B1/ko active Active
- 2015-11-17 SG SG11201703806XA patent/SG11201703806XA/en unknown
- 2015-11-17 ES ES15860676T patent/ES2947819T3/es active Active
- 2015-11-17 DK DK15860676.4T patent/DK3220916T3/da active
- 2015-11-17 EA EA201791095A patent/EA201791095A1/ru unknown
- 2015-11-17 WO PCT/US2015/061194 patent/WO2016081523A1/en not_active Ceased
- 2015-11-17 MX MX2017006089A patent/MX383484B/es unknown
- 2015-11-17 IL IL304252A patent/IL304252B2/en unknown
- 2015-11-17 LT LTEPPCT/US2015/061194T patent/LT3220916T/lt unknown
- 2015-11-17 EP EP15860676.4A patent/EP3220916B1/en active Active
- 2015-11-17 EP EP23168326.9A patent/EP4272742A1/en active Pending
- 2015-11-17 BR BR112017010166-1A patent/BR112017010166A2/en not_active Application Discontinuation
- 2015-11-17 SI SI201531949T patent/SI3220916T1/sl unknown
- 2015-11-17 FI FIEP15860676.4T patent/FI3220916T3/fi active
- 2015-11-17 US US15/527,375 patent/US10786511B2/en active Active
- 2015-11-17 KR KR1020177016377A patent/KR102338802B1/ko active Active
-
2017
- 2017-05-09 IL IL252182A patent/IL252182B2/en unknown
- 2017-05-09 MX MX2021006734A patent/MX2021006734A/es unknown
-
2020
- 2020-08-20 US US16/998,144 patent/US12168014B2/en active Active
-
2021
- 2021-01-22 JP JP2021008382A patent/JP2021073241A/ja active Pending
- 2021-07-06 AU AU2021204706A patent/AU2021204706B2/en active Active
-
2023
- 2023-02-24 JP JP2023027585A patent/JP7485810B2/ja active Active
-
2024
- 2024-02-22 AU AU2024201171A patent/AU2024201171B2/en active Active
- 2024-11-08 US US18/941,480 patent/US20250064822A1/en active Pending
-
2025
- 2025-09-16 IL IL323396A patent/IL323396A/en unknown
-
2026
- 2026-04-28 AU AU2026203199A patent/AU2026203199A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL323396A (en) | Cancer treatment methods | |
| US11642349B2 (en) | Method for treating cancer | |
| CA2967664C (en) | Pharmaceutical formulations comprising inhibitors of human histone methyltransferase ezh2 | |
| HK40103478A (en) | Epz-6438 for use in a method for treating cancer | |
| HK40098963B (en) | Method for treating cancer | |
| HK40098963A (zh) | 治疗癌症的方法 | |
| EA048689B1 (ru) | Твердый фармацевтический состав для лечения рака |